Janney Capital Management LLC Has $10.42 Million Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Janney Capital Management LLC decreased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 6.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 19,621 shares of the medical research company's stock after selling 1,292 shares during the period. Janney Capital Management LLC's holdings in Thermo Fisher Scientific were worth $10,415,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in TMO. International Assets Investment Management LLC boosted its stake in shares of Thermo Fisher Scientific by 61,995.4% in the 4th quarter. International Assets Investment Management LLC now owns 1,009,671 shares of the medical research company's stock valued at $535,923,000 after purchasing an additional 1,008,045 shares during the last quarter. Loomis Sayles & Co. L P boosted its holdings in shares of Thermo Fisher Scientific by 17,046.7% during the 3rd quarter. Loomis Sayles & Co. L P now owns 973,591 shares of the medical research company's stock worth $492,803,000 after buying an additional 967,913 shares in the last quarter. Van ECK Associates Corp increased its stake in shares of Thermo Fisher Scientific by 2,567.5% in the 4th quarter. Van ECK Associates Corp now owns 352,217 shares of the medical research company's stock valued at $186,954,000 after acquiring an additional 339,013 shares in the last quarter. Rathbones Group PLC grew its holdings in Thermo Fisher Scientific by 111.0% in the third quarter. Rathbones Group PLC now owns 568,970 shares of the medical research company's stock worth $287,996,000 after purchasing an additional 299,338 shares during the period. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its holdings in shares of Thermo Fisher Scientific by 20.3% during the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 1,706,179 shares of the medical research company's stock valued at $863,617,000 after purchasing an additional 287,446 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Price Performance

TMO stock traded up $4.22 during mid-day trading on Wednesday, reaching $599.02. 1,188,727 shares of the company traded hands, compared to its average volume of 1,531,016. Thermo Fisher Scientific Inc. has a 52-week low of $415.60 and a 52-week high of $603.82. The company has a market capitalization of $228.66 billion, a P/E ratio of 38.42, a P/E/G ratio of 2.45 and a beta of 0.80. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.70 and a quick ratio of 1.33. The company has a fifty day moving average price of $576.64 and a 200-day moving average price of $540.09.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, topping analysts' consensus estimates of $4.70 by $0.41. The business had revenue of $10.35 billion for the quarter, compared to analyst estimates of $10.14 billion. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. As a group, analysts anticipate that Thermo Fisher Scientific Inc. will post 21.64 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were paid a $0.39 dividend. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.35. This represents a $1.56 dividend on an annualized basis and a yield of 0.26%. The ex-dividend date of this dividend was Thursday, March 14th. Thermo Fisher Scientific's dividend payout ratio is currently 10.01%.

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $564.72, for a total value of $5,647,200.00. Following the completion of the transaction, the chief executive officer now owns 128,485 shares of the company's stock, valued at approximately $72,558,049.20. The transaction was disclosed in a filing with the SEC, which is available through this link. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $564.72, for a total transaction of $5,647,200.00. Following the completion of the sale, the chief executive officer now owns 128,485 shares of the company's stock, valued at $72,558,049.20. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Michael A. Boxer sold 2,000 shares of the firm's stock in a transaction dated Friday, April 26th. The shares were sold at an average price of $567.94, for a total value of $1,135,880.00. Following the transaction, the senior vice president now directly owns 13,083 shares in the company, valued at $7,430,359.02. The disclosure for this sale can be found here. In the last 90 days, insiders sold 37,547 shares of company stock worth $21,541,269. 0.34% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Royal Bank of Canada raised their price objective on Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an "outperform" rating in a research note on Thursday, February 1st. Barclays lifted their price target on Thermo Fisher Scientific from $590.00 to $615.00 and gave the company an "equal weight" rating in a research note on Thursday, April 25th. Robert W. Baird lowered their price target on Thermo Fisher Scientific from $621.00 to $620.00 and set an "outperform" rating for the company in a research report on Thursday, April 25th. The Goldman Sachs Group increased their target price on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a "buy" rating in a report on Wednesday, April 10th. Finally, Deutsche Bank Aktiengesellschaft increased their price objective on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a "buy" rating in a research note on Thursday, April 25th. Five analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $607.35.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.